Earnings · US stocks
Arcutis Biotherapeutics Inc (ARQT) earnings
Arcutis Biotherapeutics Inc published its quarterly report on 2026-11-04: net profit +0.00% year on year. The stock moved -23.05% in the 3 trading days after the report.
- Report
- quarterly report
- Published
- 2026-11-04
- Net profit YoY
- +0.00%
- Result
- Neutral
Stock move after the report
Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.
| After | Return | vs index |
|---|---|---|
| 1 day | -20.70% | — |
| 3 days | -23.05% | — |
| 7 days | -17.00% | — |
Report history
Over the last 8 reports, EPS beat the consensus estimate in 6 of them. The stock rose in the 3 trading days after 2 of 8 reports (average -2.74%).
| Published | EPS YoY | EPS | EPS surprise | 3 days after | 30 days after | 30d vs index |
|---|---|---|---|---|---|---|
| 2026-11-04 | +0.00% | 0.06 | -64.36% | -23.05% | — | — |
| 2026-08-05 | — | 0.11 | +120.00% | -4.35% | -2.36% | -1.43% |
| 2026-05-06 | — | -0.09 | -55.17% | -12.12% | +8.44% | +6.68% |
| 2026-02-25 | — | 0.13 | +46.78% | -8.33% | -9.03% | -7.12% |
| 2025-10-28 | — | 0.06 | +163.63% | +26.88% | +51.53% | +51.85% |
| 2025-08-06 | — | -0.13 | +17.89% | -7.62% | +15.30% | +10.64% |
| 2025-05-06 | — | -0.20 | +4.76% | -5.52% | -4.54% | -11.45% |
| 2025-02-25 | — | -0.09 | +65.95% | +12.21% | +8.93% | +25.39% |
The last 8 reported quarters. Moves count trading days from the first tradeable session after the report; "30d vs index" is the excess return over the market index.
How to read this
Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.